https://www.selleckchem.com/pr....oducts/anlotinib-al3
More patients had grade 3/4 treatment-related AEs during the induction versus maintenance phase (ACP, 40.5% v 8.2%; ABCP, 48.6% v 21.2%; BCP, 44.7% v 11.1%). During induction, the incidence of serious AEs (SAEs) was 28.3%, 28.5%, and 26.4% in the ACP, ABCP, and BCP arms, respectively. During maintenance, SAE incidences were 20.0%, 26.3%, and 13.0%, respectively. Completion rates of the PRO questionnaires were 88% at baseline and remained ≥ 70% throughout most study visits. Across arms, patients on average reported no clini
Beğen
Yorum Yap
Paylaş
